[go: up one dir, main page]

CA2165188A1 - Selection et utilisation de peptides antiviraux - Google Patents

Selection et utilisation de peptides antiviraux

Info

Publication number
CA2165188A1
CA2165188A1 CA 2165188 CA2165188A CA2165188A1 CA 2165188 A1 CA2165188 A1 CA 2165188A1 CA 2165188 CA2165188 CA 2165188 CA 2165188 A CA2165188 A CA 2165188A CA 2165188 A1 CA2165188 A1 CA 2165188A1
Authority
CA
Canada
Prior art keywords
icp4
protein
complex
dna
tfiid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2165188
Other languages
English (en)
Inventor
Neal A. Deluca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2165188A1 publication Critical patent/CA2165188A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte au criblage et à la sélection de peptides ou de composés antiviraux potentiels. Des peptides ou composés antiviraux potentiels sont choisis en fonction de leur aptitude à interagir et à interférer avec une fonction essentielle d'une protéine virale de phénotype sauvage suite à une infection d'un hôte. Des peptides ou des composés antiviraux potentiels ou amas de ceux-ci sont criblés au cours d'un dosage de reconstitution in vitro comprenant une protéine virale de phénotype sauvagae, des facteurs cellulaires d'hôte agissant en trans ainsi qu'un fragment promoteur d'ADN approprié. Un agent antiviral potentiel présente l'aptitude à former un complexe unique protéine:protéine ou ADN:protéine par rapport à des interactions impliquant la protéine virale de phénotype sauvage en l'absence de l'agent antiviral.
CA 2165188 1993-07-09 1994-07-08 Selection et utilisation de peptides antiviraux Abandoned CA2165188A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8936093A 1993-07-09 1993-07-09
US089,360 1993-07-09

Publications (1)

Publication Number Publication Date
CA2165188A1 true CA2165188A1 (fr) 1995-01-19

Family

ID=22217233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2165188 Abandoned CA2165188A1 (fr) 1993-07-09 1994-07-08 Selection et utilisation de peptides antiviraux

Country Status (5)

Country Link
EP (1) EP0724650A4 (fr)
JP (1) JPH08512208A (fr)
AU (1) AU699168B2 (fr)
CA (1) CA2165188A1 (fr)
WO (1) WO1995002071A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869234A (en) * 1996-01-05 1999-02-09 President And Fellows Of Harvard College Method of identifying compounds which modulate herpesvirus infection
CA2223032A1 (fr) * 1997-02-21 1998-08-21 Smithkline Beecham Corporation Utilisation de ul-15 et de vp5 du hsv-1 pour la detection d'agents antiviraux
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
WO2011061590A1 (fr) 2009-11-17 2011-05-26 Hetero Research Foundation Nouveaux dérivés carboxamides comme inhibiteurs du vih
WO2011080562A1 (fr) 2009-12-29 2011-07-07 Hetero Research Foundation Nouveau aza-peptides contenant du cyclobutyl 2,2-disubstitué et/ou des dérivés alcoxy benzyle substitués comme agents antiviraux
WO2012095705A1 (fr) 2011-01-10 2012-07-19 Hetero Research Foundation Sels de qualité pharmaceutique de nouveaux dérivés de l'acide bétulinique
WO2014105926A1 (fr) 2012-12-31 2014-07-03 Hetero Research Foundation Nouveaux dérivés proline de l'acide bétulinique utilisés comme inhibiteurs du vih
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (fr) 2015-03-16 2016-09-22 Hetero Research Foundation Nouveaux triterpénone c-3 avec des dérivés amide c-28 servant d'inhibiteurs de vih
RS64915B1 (sr) 2019-02-11 2023-12-29 Hetero Labs Ltd Novi derivati triterpena kao inhibitori hiv-a

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917029D0 (en) * 1989-07-25 1989-09-13 Marie Curie Memorial Foundatio Polypeptide inhibitor of viral replication

Also Published As

Publication number Publication date
EP0724650A4 (fr) 1998-12-02
AU699168B2 (en) 1998-11-26
EP0724650A1 (fr) 1996-08-07
WO1995002071A1 (fr) 1995-01-19
AU7329494A (en) 1995-02-06
JPH08512208A (ja) 1996-12-24

Similar Documents

Publication Publication Date Title
Smith et al. ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB
Cao et al. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F
Cooper et al. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53
Arany et al. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein
Rank et al. Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB
Voit et al. Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein
Marais et al. Casein kinase II phosphorylation increases the rate of serum response factor‐binding site exchange.
Thut et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60
Metzler et al. Isolation of herpes simplex virus regulatory protein ICP4 as a homodimeric complex
Lewis et al. Adenovirus E1A proteins interact with the cellular YY1 transcription factor
Lutz et al. The product of the adenovirus intermediate gene IX is a transcriptional activator
Brown et al. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein
Yao et al. Physical interaction between the herpes simplex virus type 1 immediate-early regulatory proteins ICP0 and ICP4
Loeber et al. The zinc finger region of simian virus 40 large T antigen is needed for hexamer assembly and origin melting
CA2165188A1 (fr) Selection et utilisation de peptides antiviraux
Wang et al. Interleukin 4 regulates phosphorylation of serine 756 in the transactivation domain of Stat6: roles for multiple phosphorylation sites and Stat6 function
Dixon et al. The E1 helicase of human papillomavirus type 11 binds to the origin of replication with low sequence specificity
Lillycrop et al. Repression of a herpes simplex virus immediate-early promoter by the Oct-2 transcription factor is dependent on an inhibitory region at the N terminus of the protein
De La Cera et al. Mediator factor Med8p interacts with the hexokinase 2: implication in the glucose signalling pathway of Saccharomyces cerevisiae
WO1994019473A1 (fr) Modulateurs de l'expression genique
Malik et al. Use of transdominant mutants of the origin-binding protein (UL9) of herpes simplex virus type 1 to define functional domains
Tedder et al. Role for DNA-protein interaction in activation of the herpes simplex virus glycoprotein D gene
Song et al. The adenovirus E1A repression domain disrupts the interaction between the TATA binding protein and the TATA box in a manner reversible by TFIIB
Pohler et al. An in vivo analysis of the localisation and interactions of human p66 DNA polymerase δ subunit
Zhu et al. Overexpression of the herpes simplex virus type 1 immediate-early regulatory protein, ICP27, is responsible for the aberrant localization of ICP0 and mutant forms of ICP4 in ICP4 mutant virus-infected cells

Legal Events

Date Code Title Description
FZDE Dead